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Abstract: Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease
but the second cause of death among NAFLD patients are attributed to malignancies at both
gastrointestinal (liver, colon, esophagus, stomach, and pancreas) and extra-intestinal sites (kidney
in men, and breast in women). Obesity and related metabolic abnormalities are associated with
increased incidence or mortality for a number of cancers. NAFLD has an intertwined relationship
with metabolic syndrome and significantly contributes to the risk of hepatocellular carcinoma (HCC),
but recent evidence have fuelled concerns that NAFLD may be a new, and added, risk factor for
extra-hepatic cancers, particularly in the gastrointestinal tract. In this review we critically appraise
key studies on NAFLD-associated extra-hepatic cancers and speculate on how NAFLD may influence
carcinogenesis at these sites.
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver
disease worldwide, with an estimated global prevalence of 25% in adults and around 10% in
children [1–3]. The term NAFLD includes two distinct conditions with different histologic features
and prognoses: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) [4]; the
presence of steatohepatitis and significant fibrosis are considered harbingers of adverse outcomes
in individuals with NAFLD and are associated with an increased risk for morbidity and mortality
through hepatic and non-hepatic complications [5–7]. In descending order, the majority of deaths
in patients with NAFLD are, first, attributed to cardiovascular events, and, second, to malignancies
at both gastrointestinal (liver, colon, esophagus, stomach, and pancreas) and extra-intestinal site
(kidney in men, and breast in women), while end-stage liver disease is the third cause of death [8,9].
NAFLD is traditionally considered the hepatic manifestation of metabolic syndrome (MetS) and an
impressive body of evidence indicates an increased general risk of cancer in subjects with MetS,
particularly in the gastrointestinal tract. In this setting, NAFLD can either share common risk factors
(i.e., obesity and type 2 diabetes) or actively mediate some pathogenic mechanism, as in the case of liver
cancer (hepatocellular carcinoma, HCC). Excluding the latter one, colorectal cancer (CRC) has been
consistently associated with NAFLD thus far [10,11]. The mechanisms underlying the link between
NAFLD and risk of neoplasms are not fully elucidated but they probably stem from the bidirectional
relationship between NAFLD and MetS [12–14]. In this review we critically appraise the key studies
on the association between NAFLD and extra-hepatic cancers and speculate on how NAFLD may
influence carcinogenesis at these sites.
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2. Nonalcoholic Fatty Liver Disease (NAFLD) and Colorectal Cancer
The association between NAFLD and CRC is the best investigated in literature (details are
summarized in Table 1). Almost all of the studies showed a higher prevalence of colorectal lesions
in patients with NAFLD compared to patients without. Hwang and colleagues presented the first
evidence for an association of NAFLD with an increased rate of colorectal adenomatous polyps [15].
In their study, a population of 2917 participants was investigated via colonoscopy, abdominal
ultrasonography, and liver tests. The prevalence of NAFLD was 41.5% in the adenomatous polyp
group versus 30.2% in the control group; with multivariate analysis, NAFLD was associated with a
three-fold increased risk of colorectal adenomas. This preliminary finding was confirmed in a large
retrospective cohort study of 5.517 Korean women, where a two-fold increase in the occurrence of
adenomatous polyps and a three-fold increase in the risk of colorectal cancer was found in patients with
NAFLD compared to controls. However, the presence of NAFLD had no influence on the prognosis
of colorectal cancer and, in particular, on the disease recurrence during follow-up [16]. Among
NAFLD patients, those with histological diagnosis of NASH harbinger the most increased risk for
CRC. In a cross-sectional study patients with NAFLD, diagnosed by both proton magnetic resonance
spectroscopy and liver biopsy, had a significantly higher rate of colorectal adenomas (34.7% vs. 21.5%)
and advanced neoplasms (18.6% vs. 5.5%) than healthy controls [17]. Almost half of NAFLD patients
with advanced neoplasm had right-sided colorectal carcinoma. Importantly, CRC was more often found
in patients with NASH compared to those with simple steatosis (51.0% vs. 25.6% and 34.7% vs. 14.0%).
NASH remained associated with a higher risk of both adenomas (Odds Ratio (OR) 4.89) and advanced
neoplasms (OR 5.34) even after adjusting for demographic and metabolic risk factor, thus, the authors
concluded that screening colonoscopy should be strongly recommended in these patients [17]. In the
largest study performed so far in Europe, male patients with NAFLD had significantly more colorectal
adenomas and early colorectal cancers compared to those without NAFLD [18]. Multivariate regression
analysis confirmed an independent association of colorectal adenomas with NAFLD (OR 1.47) [17].
Data stemming from cross-sectional studies have also been replicated longitudinally. In a prospective
study where 1522 subjects underwent paired colonoscopies, while the index colonoscopy was negative
in all of them, the incidence of de novo adenoma development was increased by 45% in those with
NAFLD [19]. Lastly, a Danish cohort study evaluating the global risk of cancer in hospitalized patient
showed an increased risk of CRC in those with fatty liver compared to the general population, but no
difference was noticed between alcoholic and non-alcoholic fatty liver [20].
In contrast, only two studies failed to demonstrate an increased incidence of colorectal adenomas
in patients with NAFLD compared to healthy controls [21,22]. The first one found a higher burden
of adenomas in patients with NAFLD, but data did not reach a statistical significance, probably for
the smaller sample size and the younger median age. The second one remarkably showed a lower
prevalence of CRC in NAFLD patients but a higher risk for CRC in the presence of insulin resistance;
however it is well known that both raised alanine aminotransferase (ALT) levels and ultrasound can
underestimate the diagnosis of NAFLD.
Overall, it appears that NAFLD patients are more likely to have multiple polyps [23], more
often localized more in the right and transverse segments of colon [17,23]; importantly, patients with
histologic diagnosis of NASH are at higher risk for adenomatous polyps with high grade dysplasia
(HGD) compared to those with simple fatty liver [17]. The relationship between NAFLD and CRC
once again emphasizes the importance of a healthy lifestyle to prevent and treat the MetS and its
systemic manifestations. Certainly these data suggest that NAFLD patients should undergo a closer
surveillance for CRC risk according to screening guidelines [24]. If the evidence of this association
will be further confirmed in larger population studies, probably these patients should be screened in
advance and total colonoscopy considered as the preferred screening method, as neoplasms are more
commonly found in the proximal colon [19,24].
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Table 1. Principal studies on the association between nonalcoholic fatty liver disease (NAFLD) and colorectal neoplasms *.
Study Country Type of Study Population Enrolled Exclusion Criteria NAFLDDiagnosis
Prevalence of Colorectal Lesions in Patients with NAFLD vs.
Patients without NAFLD
Bhatt BD
et al. [23]
(2015)
USA Retrospective 591 pts who completed LT evaluation(68 NAFLD vs. 523 non-NAFLD)
<50 years old at LT; IBD; history of
multiple/recurrent adenomas; family history of
CRC; known cancer-predisposing gene alteration;
history of solid organ transplant; HIV pts; personal
history of cancer
Biopsy + clinical
criteria
Polyps prevalence: 59% vs. 40%; p < 0.003.
OR (Odds Ratio) 2.16; p = 0.003
Adenomatous polyps prevalence: 32% vs. 21%; p = 0.04.
OR 1.95, p = 0.02
Basyigit S
et al. [22]
(2015)
Turkey Prospectiveobservational
127 consecutive pts who underwent
colonoscopy
Other causes of hepatic disease; incomplete
colonoscopy; IBD; active gastrointestinal bleeding;
history of colorectal surgery; history of CRC;
hereditary cancer syndrome
US Adenomas prevalence: 20% vs. 25.8%. OR 1CRC prevalence: 4.6% vs. 24.2%. OR 1
Lin XF
et al. [25]
(2014)
China
Retrospective
and consecutive
cohort study
2315 community subjects who
underwent a routine colonoscopy
(263 NAFLD vs. 2052 non-NAFLD)
History of CRC, adenoma and polyp; history of
other extraintestinal malignancies;
contraindications to colonoscopy
US
Total colorectal lesions prevalence: 90.0% vs. 93.3%
Adenomatous polyps prevalence: 44.5% vs. 55.7%
CRC prevalence: 29.3% vs. 18%; p = 0.001. OR 1.868;
95% CI 1.360–2.567; p < 0.05
Wong
VW-S et al.
[17] (2012)
China Cross-sectional
380 community pts + consecutive pts
with biopsy proven NAFLD (in total
199 NAFLD vs. 181-non-NAFLD)
Other causes of hepatic disease; history of CRC or
polyps; IBD; bowel symptoms including per rectal
bleeding and altered bowel habit; prior CRC
screening; contraindications to colonoscopy
Proton-magnetic
resonance
spectroscopy or
liver biopsy
Total polyps prevalence: 52.8% vs. 38.7%; p = 0.057
Adenomatous polyps prevalence: 34.7% vs. 21.5%;
p = 0.043. OR 1.61; 95% CI 0.9–2.9; p = 0.11
Villous polyps prevalence: 6% vs. 0.6%; p = 0.042 High grade
dysplasia polyps prevalence: 18.1% vs. 5%; p = 0.002
Advance neoplasm prevalence: 18.6% vs. 5.5%; p = 0.005.
OR 3.04; 95% CI 1.29–7.2; p = 0.011 CRC 1% vs. 0.6%; p = 0.65
Stadlmayr
A et al.
[18] (2011)
Austria Cross-sectional
1211 consecutive pts who underwent
screening colonoscopy (632 NAFLD
vs. 597 non-NAFLD)
Incomplete colonoscopy; recent colorectal
polypectomy, asymptomatic IBD; extraintestinal
malignancies
US + exclusion of
other causes of
hepatic disease
Total colorectal lesions prevalence: 34% vs. 21.7%; p < 0.001
Tubular adenoma prevalence in men: 34.6% vs. 23.7%; p = 0.006
Rectum adenoma prevalence in men: 11% vs. 3%; p = 0.004
CRC prevalence in men: 1.6% vs. 0.4%; p < 0.001
Lee YI
et al. [16]
(2011)
South
Korea
Retrospective
cohort study
5517 women who underwent life
insurance company health
examinations (831 NAFLD vs. 4686
non-NAFLD)
Other causes of hepatic disease; history of receiving
previous medical insurance benefits
US + exclusion of
other causes of
hepatic disease
Adenomatous polyps incidence: 628 vs. 185.2/105 person year.
RR 1.94; 95% CI 1.11–3.40
CRC incidence: 233.6 vs. 27/105 person year. RR 3.08;
95% CI 1.02–9.34
Touzin
NT et al.
[21] (2011)
USA Retrospectivecohort study
233 patients who underwent
screening colonoscopies (94 NAFD
vs. 139 non-NAFLD)
Not available US + liver biopsy Adenomas prevalence: 24.4% vs. 25.1%; p = 1
Huang
KW et al.
[19] (2012)
Taiwan Retrospectivecohort study
1522 pts with two consecutive
colonoscopies (216 with colorectal
adenoma vs. 1306 without colorectal
adenoma after negative baseline
colonoscopy)
History of colorectal adenoma or CRC; adenomas
during baseline colonoscopy; incomplete medical
record data; alcohol consumption >20 g/day
US + exclusion of
other causes of
hepatic disease
NAFLD prevalence: 55.6% vs. 38.8%; p < 0.05. OR = 1.45;
95% CI 1.07–1.98; p = 0.016
Hwang
ST et al.
[15] (2009)
South
Korea Cross-sectional
2917 pts who underwent routine
colonoscopy (556 with polyps vs.
2361 without polyps)
Incomplete colonoscopies; history of polypectomy;
IBD; history of cancer; cancer detected during the
study; pts with anticoagulant therapy; other causes
of hepatic disease
US NAFLD prevalence: 41.5% vs. 30.2%; p < 0.001. OR, 1.30;95% CI 1.02–1.66; p = 0.034
* CI, confidence interval; CRC, colorectal cancer; IBD, intestinal bowel disease; LT, liver transplant; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; pts, patients; RR: relative
risk; US, ultrasound.
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3. NAFLD and Cancers in Other Sites
The association of NAFLD with other extra-hepatic cancers is less proven. In the previously-
mentioned Danish study all-cancers risk was increased by 70% in subjects with fatty liver, either
alcoholic or non-alcoholic [20]; however, those with NAFLD had a higher risk of pancreatic and kidney
cancer (standardized incidence ratio (SIR) 3; 95% confidence interval (CI) 1.3–5.8 and SIR 2.7; 95%
CI 1.1–5.6, respectively), malignant melanoma (SIR 2.4; 95% CI 0.8–5.6) and cancer metastases from
primary unspecified sites (SIR 6.3; 95% CI 1.3–18.4), while those with alcoholic fatty liver had a higher
risk for lung and breast cancer (SIR 2.2; 95% CI 1.7–2.8 and SIR 1.5; 95% CI 0.9–2.2, respectively).
The latter observation contrasts with another study where a higher prevalence of breast cancers was
observed in patients with ultrasound diagnosed NAFLD compared with healthy controls (63% vs. 48%,
respectively) [26]. The burden of data available is currently too limited to draw definite conclusions
about a specific role of NAFLD, as the link can be mediated by visceral obesity, which in turn is strongly
associated to fatty liver in the so-called “central-axis” of obesity. A recent review summarized the
well-recognized role of visceral obesity in the onset and development of various cancers [27], including
CRC [28–31], esophageal [32–38] and pancreatic cancer [39], breast [40], thyroid [41], and probably
prostate cancer [42]. What is currently unknown is whether both NAFLD and visceral obesity are just
markers of an increased risk of cancers or also active players in this process. With this caveat in mind,
we will briefly examine the association between NAFLD, visceral obesity, and cancers other than CRC.
3.1. Esophageal and Gastric Cancer
Esophageal cancer is the eighth most common form of cancer worldwide, and the World Cancer
Research Fund has identified obesity as a major risk factor, able to increase the risk up to four-fold
compared with lean populations [43]. Several more recent studies suggest a stronger impact of visceral
fat distribution rather than body mass index (BMI) per se [37,44,45], but no study specifically examined
hepatic fat. Strikingly, the association between visceral obesity and esophageal adenocarcinoma is
independent of gastro-oesophageal reflux disease (GORD), and possibly mediated by adipose tissue
insulin resistance and chronic inflammation [32,46,47]. A possible direct link between NAFLD and
gastric cancer has been suggested in a recent study, performed on 1840 patients undergoing upper
endoscopies over a six-month time frame; despite the limited number of gastric cancer diagnosed,
the prevalence of NAFLD in subjects with gastric cancers was higher compared to the average in the
Turkish population [48].
3.2. Pancreatic Cancer
In 2007 the World Cancer Research Fund/American Institute for Cancer Research (WCRF)
definitively established the association between pancreatic cancer and overweight/obesity.
A meta-analysis published in 2012 showed a linear increase between pancreatic cancer risk and
waist circumference, with a relative risk (RR) of 1.11 (95% CI 1.05–1.18) for every 10 cm increase,
and waist-to-hip ratio, with a RR of 1.19 (95% CI 1.09–1.31) for every 0.1 unit increment [39]. In a
meta-analysis performed in 2012, MetS has been identified itself as a neoplastic risk factor, with
a RR of 1.58 (p < 0.0001) for pancreatic cancer in female gender, possibly mediated by decreased
physical activity, consumption of high-calorie dense foods, high dietary fat intake, low fiber intake, and
oxidative stress [49]. As for esophageal cancer, NAFLD can be implicated in this association, although
no direct evidence is yet available.
3.3. Renal Cancer
In addition to smoking and dietary habits, whose association with renal cancer is well established,
some of the components of MetS, such as obesity and hypertension, have been recognized etiological
factors and listed in specialist guidelines [50,51]. In a large study of seven European cohorts, high
level of a metabolic risk score, based on the combination of BMI, blood pressure, and plasma levels of
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glucose, total cholesterol and triglycerides, was linearly and positively associated to higher incidence
of renal cell cancer (risk increase per standard deviation of metabolic risk score increment: 43% in men
and 40% in women) [52]. In patients with cT1a renal cell carcinoma visceral fat, assessed by computed
tomography (CT) scan, is strongly associated with Fuhrman grade, the most frequently used neoplastic
nuclear grading system for kidney, and is an independent predictor of high-grade renal cell carcinoma
(RCC) [53]. In a study performed on 118 consecutive patients undergoing surgical treatment for RCC,
adiponectin levels are inversely proportional to the severity of disease, with the lower levels in patients
with metastatic cancer [54].
3.4. Breast Cancer
The association between breast cancer risk in postmenopausal women and components of MetS
has been provided by several large studies [49,55–57]. In combined analyses of two case-control
study on 3869 postmenopausal women with breast cancer and 4082 postmenopausal control cases,
authors registered a higher neoplastic risk in women with MetS than those without (OR 1.75; 95% CI
1.37–2.22). In the analysis of distribution of cases and controls according to individual components of
the syndrome, the resulting corresponding odds ratios were 1.33 (95% CI 1.09–1.62) for diabetes, 1.19
(95% CI 1.07–1.33) for hypertension, 1.08 (95% CI 0.95–1.22) for hyperlipidemia, 1.26 (95% CI 1.11–1.44)
for BMI ě 30 kg/m2, and 1.22 (95% CI 1.09–1.36) for waist circumference ě88 cm [56]. In a study
on 2092 patients, surgically treated for stage I–III invasive breast cancer in the previous five years
and followed-up over 2.8 years on average, MetS appeared a major determinant of the occurrence of
additional related events, such as specific mortality, presence of distant metastasis, or local recurrences
and incidence of contralateral breast cancer [58]. Although each component was associated with an
increased risk of cancer recurrence, the risk associated with the full syndrome was the highest, likely
to be the expression of a general dysmetabolic condition rather than of a specific trait.
3.5. Prostate Cancer
The link between dysmetabolic factors, NAFLD and prostate cancer is controversial. In a
systematic review and meta-regression analysis, including 31 cohort and 25 case-control, for every
five kg/m2 increment in BMI, authors described a 1.05 relative risk (95% CI 1.01–1.08), higher in
patients with progressed diseases than localized diseases [59]. Two studies specifically investigated the
role of NALFD. In the first one, NAFLD was found to be protective against neoplastic recurrence after
radical prostatectomy for prostate cancer in 293 consecutive patients [60]. The NAFLD group showed
significantly longer time-to-recurrence compared with patients without NAFLD both in the training
and validation set (hazard ratio: 0.33 and 0.22; 95% CI 0.16–0.69, and 95% CI 0.11–0.43, respectively).
The second one analyzed the development of malignancies and the specific site of disease in 1600
US-defined NAFLD subjects and in 1600 matched hepatitis C virus (HCV)-infected patients: prostate
cancer developed in 12.6% of NAFLD compared to 3.5% in HCV patients [61], and the incidence of
prostate cancer in NAFLD was higher than in the general population.
4. Putative Role of Insulin Resistance and Gut Microbiota in the Development of Extra-Hepatic
Cancers in NAFLD
Although the most extensive evidence of a possible mechanistic link between NAFLD and
extra-hepatic carcinogenesis currently comes from data on the pro-inflammatory and pro-carcinogenic
effects of insulin resistance (IR), gut microbiota has been recently identified as a novel and intriguing
player in the development of obesity, NAFLD and several types of cancer (details are summarized
in Table 2). Patients with NAFLD are characterized by dysbiosis [62] and the liver stays at the
cross-road of the complex interaction between changes in microbiota composition, IR, inflammation,
and carcinogenesis [63,64]. Dysbiosis has been found in patients with colon cancer [65] and the
possible correlation has been widely studied. Quantitative and qualitative alterations of gut microbiota
lead to increased intestinal permeability through several mechanisms, including the regulation of
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tight junctions, such as zonulin-1, and occluding by toll like receptor 2 (TLR2) in the ileum. These
alterations favor the translocation of bacterial metabolites and activation of TLRs via the recognition of
microorganism-associated molecular patterns (MAMPs) and can promote tumorigenesis through the
reduced release of the inflammasome-derived interleukin 18 (IL-18) and the increased IL-6 signaling
which, in turn, protects normal and premalignant cells from apoptosis [11,66,67].
Table 2. Putative mechanisms linking NAFLD and extra-hepatic cancers.
Mechanism Effects Extra-Hepatic Site
Insulin resistance
Ò IGF-1 axis Proliferative and anti-apoptoticeffects
Prostate/colorectal/lung/Breast cancers,
Barrett’s esophagus, esophageal
adenocarcinoma
Dysfunctional adipose tissue
Ó adiponectin/caspase activation
Ó adiponectin/TNF-α
Ò leptin/MAPK
Ò resistin/NF-κB
Anti-apoptotic effects
Proliferation and angiogenesis
Invasiveness, motility,
lamellipodia formation
Gastrointestinal and extra-intestinal cancer
Gastrointestinal and extra-intestinal cancer
Colon/breast cancer, Barrett’s esophagus,
esophageal adenocarcinoma
Breast/gastrointestinal and non-small cell
lung cancers
Inflammation
IL-6/JAK/STAT3 and IL-6/MAPK
TNF-α/Wnt/β-catenin
Proliferation
Angiogenesis, differentiation and
metastasis development
Renal/gastric/colorectal cancers
Colorectal cancer
Gut microbiota
MAMPs/TLRs
Inflammasome-derived IL-18
Inflammation
Anti-apoptotic effects
Colon cancer
Colon cancer
IGF-1, insulin growth factor-1; IL, interleukin; MAMPs, microorganism-associated molecular patterns; MAPK,
mitogen-activated protein kinase; NF-κB, nuclear factor-κ B; STAT3, signal transducer and activator of
transcription 3; TLRs, toll-like receptors; TNF-α, tumor necrosis factor-α.
It is well known that host diet significantly impacts on gut microbial composition. Diet-induced
NAFLD may be mediated by the myeloid differentiation factor 88 (MyD88)-dependent pathway [68].
This factor is an adaptor molecule, essential for the signaling through TLRs. It is recruited after the
interaction among the microorganism-associated molecular patterns (MAMPs) and TLRs (particularly
TLR4) and promotes the transcription of several pro-inflammatory cytokines through the activation of
NF-κB or c-Jun NH2-terminal kinase (JNK) leading to the induction of IR. Loss-of-function mutation or
knockout mice in TLR4 prevents IR induced by obesity underlying the important role of this receptor
in the modulation of the innate immune system.
NAFLD and visceral adipose tissue are the main components of the axis of central obesity.
In this setting, low-grade chronic inflammation and insulin resistance (IR) create a microenvironment
suitable for cancer development through the stimulation of the insulin growth factor-1 (IGF-1) axis
by hyperinsulinemia [9,69–71]. Through its proliferative and anti-apoptotic effects, this pathway can
boost mutations favoring carcinogenesis [72,73]. Elevated serum levels of IGF-1 have been associated
with prostate [74,75], colorectal [76], lung [77], and breast cancer [78]. Importantly, the insulin/IGF
system is able to influence the risk of Barrett’s esophagus and of esophageal adenocarcinoma [37,79,80],
although there is no full agreement about this [81].
Several adipokines, involved in the modulation of metabolism, inflammation and fibrogenesis,
can also be involved in carcinogenic processes. Adiponectin has anti-carcinogenic effects mediated by
its ability to stop colon cancer cell growth through the AMPc-activated protein kinase (AMPK) and to
induce a caspase-dependent pathway resulting in endothelial cell apoptosis. Adiponectin can also
directly inhibit tumor necrosis factor α (TNF-α), involved in tumor cell proliferation and angiogenesis.
Since NAFLD patients have reduced serum levels of adiponectin, the above described mechanisms
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represent an interesting link between NAFLD and cancer development at both gastrointestinal and
extra-intestinal site.
The pro-carcinogenic effects of leptin, especially in the presence of low adiponectin levels, have
been widely investigated. In obese animal models, leptin acts as a growth factor for CRC at early stages
through the activation of signal transducer and activator of transcription 3 (STAT 3) pathway [82].
In human colon cancer cells leptin is able to promote motility and invasiveness by activation of
mitogen-activated protein kinase (MAPK) pathway [83]. A case-cohort study in post-menopausal
women with CRC demonstrated that high plasma concentrations of leptin were associated with an
increased risk for CRC [84]. In obese subjects the combination of high leptin and low adiponectin
levels may also increase the risk of Barrett’s esophagus [85–90] and esophageal adenocarcinoma by
enhanced cell proliferation and reduced apoptosis via extracellular signal-regulated kinase (ERK),
p38 MAPK, phosphatidylinositol 31-kinase/Akt, and Janus kinase-2 (JAK2)-dependent activation of
cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2). The association between leptin serum levels
and the size of breast tumors has been summarized in a recent review [91]; higher leptin levels are
related to a more aggressive disease, presence of metastasis and a lower survival rate [92] mostly in
obese patients [93].
Finally, resistin can also be linked to obesity-related malignancies via activation of nuclear factor-κ
B (NF-κB) pathway and amplification of the procarcinogenic effects of interleukin (IL)-1, IL-6 and
TNF-α [94]. To date, a putative role of resistin has been suggested in breast cancer [94], non-small cell
lung cancer [95] and in gastrointestinal tumors [96].
The low-grade chronic inflammation associated with IR also favors macrophages recruitment
and massive release of several proinflammatory cytokines, such as IL-6 and TNF-α, into the systemic
circulation. IL-6 induces the Janus kinase/signal transducer and activator of transcription (JAK/STAT)
and MAPK pathways, stimulating cell proliferation and tumor progression, while TNF-α influences
cancer angiogenesis, metastasis development and cell survival, growth, and differentiation [97–99].
Animal models have shown a relationship between TNF-α and several malignancies [100–102]
including colorectal cancer [103]. Obese mice have higher TNF-α levels in the colonic mucosa,
leading to β-catenin stabilization and increased transcription of the downstream Wnt pathway gene
c-Myc [104]. IL-6 has been linked to renal cell carcinoma [105], gastric cancer [106], and colorectal
cancer [107,108], through its modulation of several genes involved in proliferation, survival, and
angiogenesis [109].
In consideration of the above described mechanisms, the increased risk of gastrointestinal cancers
associated to NAFLD does not appear causal, although more extensive studies are required to
demonstrate a direct link between NAFLD and cancers at various sites.
5. Conclusions
NAFLD is a complex multifactorial disease closely interrelated with obesity and type 2 diabetes,
and shares with them a significant increased risk of several types of cancer. Beyond the risk of HCC,
clearly mediated by NASH, substantial evidence is accumulating for a role of NAFLD as independent
risk factor for cancers, particularly in the gastrointestinal tract. Once again, these preliminary, but
intriguing, data convey that NAFLD patients require a multidisciplinary evaluation with a particular
attention to the development of extra-hepatic complications. Further studies are necessary to better
define high-risk NAFLD patients and effective screening strategies, but we encourage health care
providers taking care of NAFLD patients to be vigilant for any signs and symptoms of cancer,
particularly colorectal, and refer the patients for further assessment and management.
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Abbreviations
AMPK AMPc-activated protein kinase
CI confidence interval
COX-2 cyclooxygenase 2
CRC colorectal cancer
ERK extracellular signal-regulated kinase
HCC hepatocellular carcinoma
HGD high grade dysplasia
IBD inflammatory bowel disease
IGF insulin growth factors
IL interleukin
IR insulin resistance
LT liver transplant
MAMPs microorganism-associated molecular patterns
MAPK mitogen-activated protein kinase
MetS metabolic syndrome
mTOR mammalian target of rapamycin
NAFL non-alcoholic fatty liver
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
NF-kB nuclear factor-κ B
OR odds ratio
PGE2 Prostaglandin E2
RR relative risk
SIR standardized incidence ratio
STAT3 signal transducer and activator of transcription
TNF-α tumor necrosis factor α
US ultrasound
JAK2 Janus kinase-2
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